Table 1.
Baseline characteristics of the study group (n = 52)
| Baseline characteristics | No. (%) | ||
|---|---|---|---|
| Elderly patients (n = 23) | Younger patients (n = 29) | p value | |
| Age (years): median, range | 82 [80–90] | 58.3 [32–77] | |
| Sex: male/female | 14/9 | 16/13 | 0.68a |
| M Stage | |||
| M1a | 7 (31) | 4 (14) | |
| M1b | 4 (17) | 5 (18) | 0.30b |
| M1c | 12 (52) | 20 (69) | |
| Cerebral metastasis | 3 (13) | 7 (25) | |
| Active | 1 | 1 | |
| Inactive | 2 | 6 | |
| BRAF status | |||
| BRAF-mutated (V600) | 2 (9) | 8 (26) | 0.07b |
| BRAF-WT | 21 (91) | 17 (59) | |
| NA | 4 (14) | ||
| Lactate dehydrogenase level | |||
| < Upper limit of normal range | 5 (22) | 16 (55) | 1b |
| > Upper limit of normal range | 1 (4) | 5 (17) | |
| NA | 17 (74) | 8 (28) | |
| Previous systemic therapy | |||
| Ipilimumab as first-line therapy | 9 (39) | 5 (17) | |
| Ipilimumab as second-line therapy or more | |||
| After antiPD1 | 2 (9) | 1 (3) | 0.21b |
| After targeted therapy | 3 (13) | 8 (27) | |
| After chemotherapy | 9 (39) | 15 (51) | |
| Number of doses of ipilimumab | |||
| Median, range | 4 [2–8] | 3.8 [1–8] | |
| Geriatric assessment | |||
| ECOG status | |||
| 0 | 7 (31) | 9 (31) | |
| 1 | 15 (65) | 15 (51) | 0.55b |
| 2 | 1 (4) | 4 (14) | |
| ≥ 3 | 0 | 1 (3) | |
| Comorbidities | |||
| Charlson score: median, range | 0 [0–3] | 0 [0–3] | |
| Myocardial infarction | 1 | 0 | |
| Congestive heart failure | 2 | 2 | |
| Peripheral vascular disease | 1 | 1 | |
| Cerebrovascular disease | 1 | 0 | |
| Dementia | 0 | 0 | |
| Connective tissue disease | 0 | 0 | |
| Chronic pulmonary disease | 2 | 2 | |
| Peptic ulcer disease | 1 | 1 | |
| Liver disease | 0 | 0 | |
| Diabetes | 1 | 5 | |
| Renal disease | 0 | 0 | |
| Other tumor (non-metastatic) | 3 | 1 | |
| BMI | |||
| Median, range | 25.7 [16–41, 6] | 25.7 [15, 92–41, 23] | |
| Personal situation | |||
| With family at home | 14 (61) | 11 (38) | |
| Alone at home | 9 (39) | 17 (62) | |
| Institution | 0 | 0 | |
| NA | 0 | 1 | |
| Serum albumin (g/L) | |||
| Median, range | 39.7 [33–43, 3] | 44.5 [34–45, 7] | |
| > 30 | 16 (70) | 14 (48) | |
| ≤ 30 | 0 | 0 | |
| NA | 7 (30) | 15 (52) | |
| Lymphocyte count (g/L) | |||
| Median, range | 1.2 [0.49–4.12] | 1.4 [0.6–4.2] | |
BMI body mass index, NA not available, WT wild type
aIndependent t test
bFisher’s exact test